Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)

BACKGROUND: We conducted a phase II trial to evaluate the efficacy of dasatinib, a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). METHODS: Eligibility requirements were Karnofsky performance status ≥60%; no concurrent hepatic enzyme-inducing anticonvulsants; p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Lassman, Andrew B., Pugh, Stephanie L., Gilbert, Mark R., Aldape, Kenneth D., Geinoz, Sandrine, Beumer, Jan H., Christner, Susan M., Komaki, Ritsuko, DeAngelis, Lisa M., Gaur, Rakesh, Youssef, Emad, Wagner, Henry, Won, Minhee, Mehta, Minesh P.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762006/
https://ncbi.nlm.nih.gov/pubmed/25758746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados